Advanced search
Publication Cover
Expert Review of Vaccines Volume 12, 2013 - Issue 12
Submit an article Journal homepage
348
Views
15
CrossRef citations to date
0
Altmetric
Reviews

Economic evaluations of hepatitis A vaccination in middle-income countries

Auliya A SuwantikaUnit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The Netherlands;Faculty of Pharmacy, University of Padjadjaran, Bandung, Indonesia
,
Selen YegenogluPharmacy Management Department, Faculty of Pharmacy, Hacettepe University, Ankara, Turkey
,
Arthorn RiewpaiboonDivision of Social and Administrative Pharmacy, Department of Pharmacy, Faculty of Pharmacy, Mahidol University, Bangkok, Thailand
,
Hong-Anh T TuInstitute of Health Policy, Management and Evaluation (IHPME), University of Toronto, Toronto, ON, Canada
&
Maarten J PostmaUnit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, University of Groningen, Groningen, The NetherlandsCorrespondence[email protected]
Pages 1479-1494 | Published online: 09 Jan 2014

References

  • Koff RS. Hepatitis A. Lancet 341, 1643–1649 (1998).
  • Lemon SM. Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin. Chem. 43(8(B)), 1494–1499 (1997).
  • Luyten J, Beutels P. Costing infectious disease outbreaks for economic evaluation, A review for hepatitis A. Pharmacoeconomics 27 (5), 379–389 (2009).
  • WHO. HepatitisA vaccines: WHO position paper. Weekly Epidemiol. Rec. 75(5), 38–42 (2000).
  • Verhoef L, Boot HJ, Koopmans et al. Changing risk profile of hepatitis A in The Netherlands: a comparison of seroprevalence in 1995–1996 and 2006–2007. Epidemiol. Infect. 139, 1172–1180 (2011).
  • MacIntyre CR, Burgess MA, Hull B et al. Hepatitis A vaccination options for Australia. J. Pediatr. Child Health 39, 83–97 (2003).
  • Erdo?an MS, Otkun M, Tatman-Otkun M et al. The epidemiology of hepatitis A virus infection in children, in Edirne, Turkey. Eur. J. Epidemiol. 19, 267–273 (2004).
  • Zahdi MR, Junior IM Jr, Maluf EM. Hepatitis A: the costs and benefits of the disease prevention by vaccine, Paraná, Brazil. Braz. J. Infect. Dis. 13(4), 257–261 (2009).
  • Hendrickx G, Van Herck K, Vorsters A et al. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J. Viral Hepat. 15( Suppl. 15), 1–15 (2008).
  • Carrilho FJ, Clemente CM, Da Silva LC. Epidemiology of hepatitis A and E virus infection in Brazil. Gastroenterol Hepatol. 28(3), 118–125 (2005).
  • Rosenthal P. Cost-effectiveness of hepatitis A Vaccination in children, adolescents, and adults. Hepatology 37(1), 44–50 (2003).
  • Deneke MG, Arguedas MR. Hepatitis A and considerations regarding the cost effectiveness of vaccination programs. Expert Rev. Vaccines 2(5), 661–672 (2003).
  • Luyten J. Cost-effectiveness of hepatitis A vaccination for adults in Belgium. Vaccine 30(42), 6070–6080 (2012).
  • de Soárez PC, Sartori AMC, Santos A et al. Contributions from the systematic review of economic evaluations: the case of childhood hepatitis A vaccination in Brazil. Cad. SaúdePública. 28(2), 211–228 (2012).
  • Anonychuk AM, Tricco AC, Bauch CT et al. Cost-effectiveness analyses of hepatitis A vaccine, A systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies. Pharmacoeconomics 26(1), 17–32 (2008).
  • Bos JM, van Alphen L, Postma MJ. The use of modeling in the economic evaluation of vaccines. Expert Rev. Pharmacoecon. Outcomes Res. 2(5), 443–455 (2002).
  • Ozawa S, Mirelman A, Stack ML et al. Cost-effectiveness and economic benefits of vaccines in low- and middle-income countries: a systematic review. Vaccine 31(1), 96–108 (2012).
  • Nakamura MM, Tasslimi A, Lieu TA et al. Cost effectiveness of child pneumococcal conjugate vaccination in middle-income countries. Int. Health 3, 270–281 (2011).
  • Beutels P, Edmunds WJ, Antoñanzas F et al. Economics evaluation of vaccination programmes, A concensus statement focusing on viral hepatitis. Pharmacoeconomics 20(1), 1–7 (2002).
  • Polinder S, Segui-Gomez M, Toet H et al. Systematic review and quality assessment of economic evaluation studies of injury prevention. Accid. Anal. Prev. 45, 211–221 (2012).
  • Sartori AMC, De Soarez PC, Novaes HMD et al. Cost-effectiveness analysis of universal childhood hepatitis A vaccination in Brazil: regional analyses according to the endemic context. Vaccine 30(52), 7489–7497 (2012).
  • Valenzuela MT, Jacobs RJ, Arteaga O et al. Cost-effectiveness of universal childhood hepatitis A vaccination in Chile. Vaccine 23(32), 4110–4119 (2005).
  • Quezada A, Baron-Papillon F, Coudeville L et al. Universal vaccination of children against hepatitis A in Chile: a cost-effectiveness study. Rev. Panam. Salud. Publica. 23(5), 303–312 (2008).
  • Ellis A, R?ttimann RW, Jacobs RJ et al. Cost-effectiveness of childhood hepatitis A vaccination in Argentina: a second dose is warranted. Rev. Panam. Salud. Publica. 21(6), 345–356 (2007).
  • Lopez E, Debbag R, Coudeville L et al. The cost-effectiveness of universal vaccination against hepatitis A in Argentina: results of a dynamic health-economic analysis. J. Gastroenterol. 42, 152–160 (2007).
  • Zhuang GH, Pan XJ, Wang XL. A cost-effectiveness analysis of universal childhood hepatitis A vaccination in China. Vaccine 26(35), 4608–4616 (2008).
  • Teppakdee A, Tangwitoon A, Khemasuwan D et al. Cost-benefit analysis of hepatitis A vaccination in Thailand. Southeast Asian J. Trop. Med. Public Health 33(1), 118–126 (2002).
  • El-Karaksy H, El-Sayed R, El-Raziky M et al. Cost-effectiveness of prescreening versus empirical vaccination for hepatitis A in Egyptian children with chronic liver disease. East Mediterr. Health J. 14(4), 804–809 (2008).
  • Soogarun S, Wiwanitkit V. Vaccinating Thai adolescents against hepatitis A: is it cost-effective? Southeast Asian J. Trop. Med. Public Health 33( Suppl. 33), 145–148 (2002).
  • Jacobsen KH, Koopman JS. Declining hepatitis A seroprevalence: a global review and analysis. Epidemiol. Infect. 132, 1005–1022 (2004).
  • Jacobsen KH, Wiersma ST. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 28(41), 6653–6657 (2010).
  • Simoens S. Health economics assessment: a methodological primer. Int. J. Environ. Res. Public Health 6, 2950–2966 (2009).
  • Bärnighausen T, Bloom DE, Canning D et al. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenza type b vaccine. Vaccine 29, 2371–2380 (2011).
  • Drummond M, Chevat C, Lothgren M. Do we fully understand the economic value of vaccines? Vaccine 25(32), 5945–5957 (2007).
  • Suwantika AA, Tu HT, Postma MJ. Cost-effectiveness of rotavirus immunization in Indonesia: taking breastfeeding patterns into account. Vaccine 31(32), 3300–3307 (2013).
  • Jacobs RJ, Meyerhoff AS, Zink T. Hepatitis A immunization strategies: universal versus targeted approaches. Clin. Pediatr. 44(705), 1–6 (2005).
  • Samandari T, Bell BP, Armstrong GL. Quantifying the impact of hepatitis A immunization in the United States, 1995–2001. Vaccine 22(31–32), 4342–4350 (2004).
  • Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics 109(5), 839–845 (2002).
  • Ginsberg GM, Slater PE, Shouval D. Cost-benefit analysis of a nationwide infant immunization programme against hepatitis A in an area of intermediate endemicity. J. Hepatol. 34(1), 92–99 (2001).
  • Van Effelterre TP, Zink TK, Hoet BJ et al. A mathematical model of hepatitis A transmission in the United States indicates value of universal childhood immunization. Clin. Infect. Dis. 43(2), 158–64 (2006).
  • Arnal JM, Frisas O, Garuz R et al. Cost effectiveness of hepatitis A virus immunization in Spain. Pharmacoeconomics 12(3), 361–373 (1997).
  • Demicheli V, Carniglia E, Fucci S. The use of hepatitis A vaccination in Italy: an economic evaluation. Vaccine 21(19–20), 2250–2257 (2003).
  • Jacobs RJ, Margolis HS, Coleman PJ. The cost-effectiveness of adolescent hepatitis A vaccination in states with the highest disease rates. Arch. Pediatr. Adolesc. Med. 154(8), 763–770 (2000).
  • Jacobs RJ, Meyerhoff AS. Comparative cost effectiveness of varicella, hepatitis A, and pneumococcal conjugate vaccines. Prev. Med. 33(6), 639–645 (2001).
  • Postma MJ, Bos JM, Beutels P et al. Pharmaco-economic evaluation of targeted hepatitis A vaccination for children of ethnic minorities in Amsterdam (The Netherlands). Vaccine 22(15–16),1862–1867 (2004).
  • Sonder GJB, Bovee LPMJ, Baayen TD et al. Effectiveness of a hepatitis A vaccination for migrant children in Amsterdam, Netherlands (1992–2004). Vaccine 24, 4962–4968 (2006).
  • Edmunds WJ, Medley GF, Nokes DJ. Evaluating the cost-effectiveness of vaccination programs: a dynamic perspective. Stat. Med. 18(23), 3263–3282 (1999).
  • Kim SY, Goldie SJ. Cost-effectiveness analyses of vaccination programmes. Pharmacoeconomics 26(3), 191–215 (2008).
  • Armstrong GL, Billah K, Rein DB et al. The economics of routine childhood hepatitis A immunization in the United States: The impact of herd immunity. Pediatrics 119, e22–e29 (2007).
  • Jacobs RJ, Greenberg DP, Koff RS et al. Regional variation in the cost-effectiveness of childhood hepatitis A immunization. Pediatr. Infect. Dis. J. 22(10), 904–914 (2003).
  • Tapia-Conyer R, Santos JI, Cavalcanti AM et al. Hepatitis A in Latin America: a changing epidemiologic pattern. Am. J. Trop. Med. Hyg. 61, 825–829 (1999).
  • Lopez E, Debbag R, Coudeville L et al. Cost-effectiveness of vaccination against hepatitis A in children: the case of Argentina (abstract). Program and abstracts of the 4th World Congress of the World Society for Pediatric Infectious Diseases. Warsaw, Poland, 1–4 September 2005.
  • Hauboldt RH. Cost Implications of Human Organ and Tissue Transplantations, An Update: 1999. Milliman & Robertson, Inc., Seattle, WA, USA (1999).
  • Berge JJ, Drennan DP, Jacobs RJ et al. The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 31(2), 469–473 (2000).
  • WHO. Who Guide for Standardization of Economic Evaluations of Immunization Programmes. WHO Press, Geneva, Switzerland, 58–68 (2008).
  • Bauch CT, Anonychuk AM, Pham BZ et al. Cost-utility of universal hepatitis A vaccination in Canada. Vaccine 25, 8536–8548 (2007).
  • Valentim J, Sartori AM, de Soárez PC et al. Cost-effectiveness analysis of universal childhood vaccination against varicella in Brazil. Vaccine 26, 6281–6291 (2008).
  • de Soárez PC, Valentim J, Sartori AM et al. Cost-effectiveness analysis of routine rotavirus vaccination in Brazil. Rev. Panam. Salud. Publica. 23, 221–230 (2008).
  • Sartori AM, de Soárez PC, Novaes HM. Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal immunization of infants in Brazil. J. Epidemiol. Community Health 66, 210–217 (2012).
  • Miller MA, Hinman AR. Cost-benefit and cost-effectiveness analysis of vaccine policy. In: Vaccines (3rd Edition). Plotkin SA, Orenstein WA ( Eds). WB Saunders, Philadelphia, PA, USA, 1074–1088 (1999).
  • Bockhold K, Riely CA, Jeffreys C. Overcoming obstacles to immunization in patients with chronic liver disease. Am. J. Med. 118(10A), 40S–45S (2005).
  • Munira SL, Fritzen SA. What influences government adoption of vaccines in developing countries. Soc. Sci. Med. 65, 1751–1764 (2007).
  • Tu HT, Woerdenbag HJ, Kane S et al. Economic evaluations of hepatitis B vaccination for developing countries. Expert Rev. Vaccines 8(7), 907–920 (2009).
  • Gravelle H, Smith D. Discounting for health effects in cost-benefit and cost-effectiveness analysis. Health Econ. 10, 581–594 (2001).
  • Smith DH, Gravelle H. The practice of discounting in economic evaluations of healthcare interventions. Int. J. Technol. Assess Health Care 17, 236–243 (2001).
  • Weinstein MC, Stason WB. Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. 296(13), 716–721 (1977).
  • Edejer TT, Baltussen R, Adam T et al. Discounting. In: Making Choices in Health: WHO Guide to Cost-effectiveness Analysis. WHO Press, Geneva, Switzerland, 83–87 (2003).
  • Brouwer WBF, van Exel NJA, Tilford JM. Incorporating caregiver and family effects in economic evaluations of child health. In: Economic Evaluation in Child Health. Oxford Scholarship Online, Oxford, UK, 1–18 (2010).
  • Gold MR, Siegel JE, Russell LB et al. In: Cost-effectiveness in Health and Medicine. Oxford University Press, NY, USA (1996).
  • Gravelle H, Brouwer WBF, Niessen L et al. Discounting in economic evaluations: stepping forward towards optimal decision rules. Health Econ. 16, 307–317 (2007).
  • Murdoch DL, Goa K, Figgitt DP. Combined hepatitis A and B vaccines, A review of their immunogenicity and tolerability. Drugs 63(23), 2625–2649 (2003).
  • Navas E, Salleras L, Gisbert R et al. Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools. Vaccine 23, 2185–2189 (2005).
  • Jacobs RJ, Gibson GA, Meyerhoff AS. Cost-effectiveness of hepatitis A-B vaccine versus hepatitis B vaccine for healthcare and public safety workers in the Western US. Infect. Control Hosp. Epidemiol. 25(7), 563–569 (2012).
  • Jacobs RJ, Rosenthal P, Meyerhoff AS. Cost effectiveness of hepatitis A/B versus hepatitis B vaccination for US prison inmates. Vaccine 22, 1241–1248 (2004).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.